Log In
BCIQ
Print this Print this
 

methylnaltrexone (Oral Relistor) (MOA-728)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionPeripheral mu opioid receptor (MOR; OPRM1) antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC); Treat opioid-induced constipation (OIC) in non-cancer patients with chronic pain
Regulatory Designation
PartnerLupin Ltd.;
Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$12,524.0M

$11,689.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/01/2015

$11,400.0M

$11,400.0M

0

03/11/2015

$1,124.0M

$289.0M

0

Get a free BioCentury trial today